ENCell’s EN001 Enters Phase 2a Trials for CMT1A
A South Korean biotech company called ENCell just gave the first patient a dose of an experimental CMT treatment called EN001, kicking off a Phase 2a clinical trial. This is a big step forward: earlier trials focused on making sure the drug was safe, and now researchers are testing whether it actually works, and at what dose.
The trial will enroll 21 patients across three major hospitals in Korea. Some will get a low dose, some a high dose, and some a placebo, so the researchers can see which dose performs best compared to no treatment. They’ll track results over 24 weeks using the CMT neuropathy score.
EN001 is a stem cell therapy made from umbilical cord cells. It’s designed to help regrow the protective myelin sheath around damaged nerves, which is what breaks down in CMT1A. Right now, there is no approved treatment that addresses the root cause of CMT. If this trial goes well, the company hopes to pursue early commercial approval.
Read the full press release here
Progress like this is a reminder of why patient participation in research infrastructure matters. The CMT Global Registry for Inherited Neuropathies exists to build the kind of patient data foundation that can accelerate trials, inform study design, and connect researchers with the CMT community worldwide. The more patients who register, the stronger that foundation becomes.
If you have CMT, joining the Registry is one of the most direct ways you can help shape the future of research and bring treatments closer to the people who need them.
Join today at joinGrin.org
0 Comments